Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

✍ Scribed by Pohl, A; El-Khoueiry, A; Yang, D; Zhang, W; Lurje, G; Ning, Y; Winder, T; Hu-Lieskoven, S; Iqbal, S; Danenberg, K D; Kahn, M; Teo, J-L; Shriki, J; Stebbing, J; Lenz, H-J

• Book ID: 111951908
• Publisher: Nature Publishing Group
• Year: 2012
• Tongue: English
• Weight: 401 KB
• Volume: 13
• Category: Article
• ISSN: 1470-269X
• DOI: 10.1038/tpj.2011.61